Bookmark and Share
BioAssay: AID 588329

Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: ATP-depletion Assay

Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, but most currently used drugs are inefficient and toxic. ..more
_
   
 Tested Compounds
 Tested Compounds
All(40)
 
 
Active(29)
 
 
Inactive(2)
 
 
Inconclusive(9)
 
 
 Tested Substances
 Tested Substances
All(40)
 
 
Active(29)
 
 
Inactive(2)
 
 
Inconclusive(9)
 
 
AID: 588329
Data Source: NCGC (PFK806)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-08-24
Hold-until Date: 2012-08-22
Modify Date: 2012-08-22

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 29
Related Experiments
Show more
AIDNameTypeComment
485367qHTS Assay to Find Inhibitors of T. brucei phosphofructokinaseConfirmatorydepositor-specified cross reference: qHTS AID
488768qHTS Assay to Find Inhibitors of T. brucei Phosphofructokinase: SummarySummarydepositor-specified cross reference: Summary AID
485368qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinaseConfirmatorysame project related to Summary assay
492961qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validationConfirmatorysame project related to Summary assay
504636Tb PFK orthogonal confirmatory assay using ATP depletion (Kinase-Glo Plus) as an alternative measure of Tb PFK activity: Hit ValidationConfirmatorysame project related to Summary assay
504637Inhibitors of T. brucei phosphofructokinase: Hit ValidationConfirmatorysame project related to Summary assay
540360Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: probe SARConfirmatorysame project related to Summary assay
588323Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Cytotoxictity in MRC5Confirmatorysame project related to Summary assay
588324Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Counter Screen against T cruzi PFKConfirmatorysame project related to Summary assay
588325Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Cytotoxictity in KB-3-1Confirmatorysame project related to Summary assay
588330Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: High ATPConfirmatorysame project related to Summary assay
588331Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: High F6PConfirmatorysame project related to Summary assay
588332Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Counter Screen against Bacillus PFKConfirmatorysame project related to Summary assay
588333Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: T. brucei in vitro Parasite AssayOthersame project related to Summary assay
624130qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Aqueous Kinetic SolubilityOthersame project related to Summary assay
624131qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Mouse Liver Microsome StabilityOthersame project related to Summary assay
624142qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Human Liver Microsome StabilityOthersame project related to Summary assay
624143qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Mouse Plasma Stability ProfilingOthersame project related to Summary assay
624144qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Human Plasma Stability ProfilingOthersame project related to Summary assay
Description:
Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, but most currently used drugs are inefficient and toxic.

Of many possible drug targets in trypanosomatid parasites, the carbohydrate metabolism pathway is seen as potentially one of the most selective, as T. brucei, when in the bloodstream of its mammalian host, is entirely dependent on the conversion of the blood sugar glucose into pyruvate for its ATP supply [1]. Oxidative metabolism involving the mitochondrial tricarboxylic acid cycle and oxidative phosphorylation are repressed in these parasites, and recent RNA interference (RNAi) experiments have shown that even partial depletion of certain individual glycolytic enzymes can lead to the death of cultured parasites [2]. One such glycolytic enzyme, phosphofructokinase (PFK), catalyzes the formation of fructose-1,6-bisphosphate (F1,6BP) and ADP from fructose-6-phosphate (F6P) and ATP, and in many metabolic circumstances makes an important contribution to the control of flux through the glycolytic pathway. As a specific glycolytic target, PFK is particularly attractive as it catalyzes the first irreversible step in glycolysis, and structural and kinetic studies have shown very substantial and essential differences from corresponding host enzymes [3], allowing for the discovery of parasite-selective inhibitors.

NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Centers Network [MLPCN]

MLPCN Grant: MH092153-01
Assay Submitter (PI): Malcom Walkinshaw, University of Edinburgh
Protocol
Substrate buffer was dispensed into white, solid 1536-well plates at 3ul/well in 0.1M triethanolamine (TEA) buffer, pH 8.0, containing final concentrations of 5 mM MgCl2, 0.01% Tween20, 0.5 mM fructose-6-phosphate (F6P) and 0.1mM ATP. Then, 23nl of compounds or DMSO were delivered to each well using a pin tool. One ul T. brucei PFK (0.1M TEA, 0.01% Tween20, 0.1% bovine serum albumin (BSA) and 1.25nM PFK, final concentrations) was then dispensed, and plates were incubated at room temperature for 45 min. The luminescent detection reagent, Kinase-Glo Plus (Promega), was then added at 2ul/well and incubated for ten minutes at room temperature. The plates were measured on a ViewLux plate reader for luminescent signal using a clear filter with a one second exposure. The %Activity was determined from the corrected luminescence values. As no specific T. brucei PFK inhibitors have been identified in the literature, 1x (1.25nM) and 0x PFK enzyme controls (untreated) were included to normalize %Activity of identified inhibitors; 0x enzyme values corresponded to 100%Activity (full inhibition), while 1x PFK enzyme values were used to normalize 0% activity (no inhibition). The Kinase-Glo Plus protocol varies from the primary screen in that it measures ATP, rather than ADP, concentration, and thus provides a measure of substrate depletion, rather than of product formation.

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent increases in luminescence, concordant with a decrease in PFK activity and ATP depletion. Inversely, active activators showed a concentration-dependent decrease in luminescence signal below 1x PFK control levels, suggestive of an increase in ATP depletion. Inactive compounds showed no effect on luminescence signal.

Keywords: T. brucei, phosphofructokinase, PFK, glycolysis, luminescence, MLSMR, MLPCN, NIH Roadmap, qHTS, NCGC
Comment
Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1PhenotypeIndicates type of activity observed: inhibitor, activator, fluorescent, cytotoxic, inactive, or inconclusive.String
2Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
3EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
4Analysis CommentAnnotation/notes on a particular compound's data or its analysis.String
5Curve_DescriptionA description of dose-response curve quality. A complete curve has two observed asymptotes; a partial curve may not have attained its second asymptote at the highest concentration tested. High efficacy curves exhibit efficacy greater than 80% of control. Partial efficacies are statistically significant, but below 80% of control.String
6Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
7Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
8Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
9Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
10Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
11Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
12Excluded_PointsWhich dose-response titration points were excluded from analysis based on outlier analysis. Each number represents whether a titration point was (1) or was not (0) excluded, for the titration series going from smallest to highest compound concentrations.String
13Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
14Activity at 0.0003244253 uM (0.000324425μM**)% Activity at given concentration.Float%
15Activity at 0.0009732759 uM (0.000973276μM**)% Activity at given concentration.Float%
16Activity at 0.00292 uM (0.00291983μM**)% Activity at given concentration.Float%
17Activity at 0.00876 uM (0.00875954μM**)% Activity at given concentration.Float%
18Activity at 0.026 uM (0.0262786μM**)% Activity at given concentration.Float%
19Activity at 0.079 uM (0.0788357μM**)% Activity at given concentration.Float%
20Activity at 0.237 uM (0.236507μM**)% Activity at given concentration.Float%
21Activity at 0.710 uM (0.709522μM**)% Activity at given concentration.Float%
22Activity at 2.129 uM (2.12857μM**)% Activity at given concentration.Float%
23Activity at 6.386 uM (6.3857μM**)% Activity at given concentration.Float%
24Activity at 19.16 uM (19.1571μM**)% Activity at given concentration.Float%
25Activity at 57.47 uM (57.4713μM**)% Activity at given concentration.Float%
26Compound QCNCGC designation for data stage: 'qHTS', 'qHTS Verification', 'Secondary Profiling'String

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: MH092153

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: